EA201992630A1 - Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf - Google Patents

Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf

Info

Publication number
EA201992630A1
EA201992630A1 EA201992630A EA201992630A EA201992630A1 EA 201992630 A1 EA201992630 A1 EA 201992630A1 EA 201992630 A EA201992630 A EA 201992630A EA 201992630 A EA201992630 A EA 201992630A EA 201992630 A1 EA201992630 A1 EA 201992630A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
eye diseases
aplnr
vegf inhibitors
treating eye
Prior art date
Application number
EA201992630A
Other languages
English (en)
Inventor
Цзинтай Цао
Юнис Чеунг
Иван Б. Лобов
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201992630A1 publication Critical patent/EA201992630A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение представляет способы лечения, профилактики или снижения тяжести заболевания глаз. Способы по данному описанию включают в себя введение субъекту, нуждающемуся в этом, терапевтической композиции, содержащей антагонист APLNR, такой как анти-APLNR антитело, в сочетании с антагонистом фактора роста эндотелия сосудов (VEGF) (например, афлиберцепт).
EA201992630A 2017-05-06 2018-05-04 Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf EA201992630A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (1)

Publication Number Publication Date
EA201992630A1 true EA201992630A1 (ru) 2020-04-29

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992630A EA201992630A1 (ru) 2017-05-06 2018-05-04 Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf

Country Status (10)

Country Link
EP (1) EP3618876A1 (ru)
JP (1) JP7161494B2 (ru)
KR (1) KR102667021B1 (ru)
CN (1) CN110709104A (ru)
AU (1) AU2018266324B2 (ru)
CA (1) CA3062418A1 (ru)
EA (1) EA201992630A1 (ru)
IL (1) IL270267B2 (ru)
MX (1) MX2019012985A (ru)
WO (1) WO2018208625A1 (ru)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9156911B2 (en) * 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2807190B1 (en) 2012-01-23 2018-12-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
WO2013153049A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides as apelin inhibitors and uses thereof
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9353163B2 (en) * 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
CA2942940A1 (en) 2014-03-20 2015-09-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
SG10201911226QA (en) * 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies

Also Published As

Publication number Publication date
AU2018266324B2 (en) 2024-02-01
CA3062418A1 (en) 2018-11-15
IL270267A (ru) 2019-12-31
IL270267B2 (en) 2024-06-01
AU2018266324A1 (en) 2019-11-28
MX2019012985A (es) 2020-01-13
JP2020518641A (ja) 2020-06-25
WO2018208625A1 (en) 2018-11-15
IL270267B1 (en) 2024-02-01
EP3618876A1 (en) 2020-03-11
KR102667021B1 (ko) 2024-05-21
JP7161494B2 (ja) 2022-10-26
CN110709104A (zh) 2020-01-17
KR20200004366A (ko) 2020-01-13

Similar Documents

Publication Publication Date Title
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201792047A1 (ru) Новые соединения
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201500364A1 (ru) Лечение глазных заболеваний
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2019001021A (es) Formulaciones de liposomas.
EA201592203A1 (ru) Способы лечения таупатии
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
CY1121933T1 (el) Υποκατεστημενες δικυκλικες διυδροπυριμιδινονες και χρηση αυτων ως αναστολεις δραστικοτητας ελαστασης ουδετεροφιλου
EA201790590A1 (ru) Гуманизированное моноклональное антитело, ингибирующее ферментативную активность сосудисто-эндотелиальной липазы
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
EA202091221A1 (ru) Способ лечения или предотвращения идиопатической полипоидной хориоидальной васкулопатии (ипхв)
EA202192400A1 (ru) Антитела против интегрина и их применение
NI201900072A (es) UNA COMPOSICION FARMACEUTICA ACUOSA DE ANTICUERPO MONOCLONAL ANTICUERPO MONOCLONAL ANTI-TNFalfa RECOMBINANTE